Studying SARS-CoV‑2 collectively


The new SARS CoV II 2019 is spread­ing rap­idly. Man­dated by the ESCMID Emer­ging Infec­tions Task Force (EITaF) and sup­por­ted by the Ger­man Infec­tious Dis­ease Soci­ety we want to bet­ter under­stand the implic­a­tions of the new vir­us on patients by sys­tem­at­ic­ally doc­u­ment­ing patient data.

show all col­lab­or­at­ors

Lean European Open Survey on SARS-CoV-2 Infected Patients
Lean European Open Sur­vey on SARS-CoV­‑2 Infec­ted Patients

no informed con­sent neces­sary (anonym­ous reports)
all hos­pit­al­ized patients includ­ing chil­dren eli­gible
ret­ro­spect­ive doc­u­ment­a­tion after dis­charge /​ death
imme­di­ate start after veri­fic­a­tion

Why

The SARS-CoV­‑2 pan­dem­ic is a major chal­lenge for med­ic­al pro­fes­sion­als world­wide, with a daily increase of new infec­tions.

Cur­rently, there is a gap of know­ledge regard­ing best pos­sible clin­ic­al man­age­ment of the infec­tion as well as pre­dic­tion and pre­ven­tion of severe out­comes.

How

We ini­ti­ated the Lean European Open Sur­vey on SARS-CoV­‑2 (LEOSS) pro­ject, a pro­spect­ive European multi-cen­ter cohort study, to get more in-depth know­ledge about the epi­demi­ology and clin­ic­al course of patients infec­ted with SARS-CoV­‑2.

Our goal is to estab­lish a quick and simple register that allows anonym­ous doc­u­ment­a­tion of patients. This data can be used to identi­fy inde­pend­ent pre­dict­ors of out­come in patients with dia­gnosed infec­tion by SARS-CoV­‑2.

The study will allow ret­ro­spect­ive inclu­sion of patients treated before ini­ti­ation of the study.

Variables

Studying SARS-CoV-2 collectively
Data Items

The eCRF will ensure the doc­u­ment­a­tion of the fol­low­ing items:

Age cat­egory, gender, eth­ni­city
Coun­try of ori­gin, coun­try of dia­gnos­is, eth­ni­city
Assumed time of con­tract­ing infec­tion
Import­ant comor­bid­it­ies
Observed stages of dis­ease (uncom­plic­ated phase, com­plic­ated phase, crit­ic­al phase, recov­ery phase), each with time to event
Baseline val­ues
and more …

Twitter Feed

Scroll to top